The Generalizability Trap in NPWT Procurement and Clinical Evaluation
When hospital surgical committees or health ministry tender boards review Negative Pressure Wound Therapy (NPWT), they are often presented with aggregated meta-analyses demonstrating statistically significant reductions in post-operative complications. However, a critical methodological gap occurs when clinical evidence collected from prophylactic closed-incision trials is generalized to open chronic wounds—or when durable open-wound vacuum trial parameters are forced onto closed surgical incisions.
Both application types share basic mechanical principles: micro-strain at the cellular level, macro-strain drawing wound edges together, continuous evacuation of interstitial fluid, and maintenance of a moist wound-healing environment 7. Furthermore, regulatory agencies treat the core hardware under identical or adjacent product categories. In the United States, FDA CDRH classifies powered NPWT suction pumps under product code OMP (21 CFR 878.4780, Class II) and non-powered systems under QPX (21 CFR 878.4683, Class II) 8.
Despite regulatory and physical similarities, the clinical endpoints, biological environments, patient populations, and device operational profiles diverge completely. Conflating the two leads to inappropriate device selection, failed tenders, unbudgeted consumable costs, and unrealistic clinical outcome expectations.
A major source of bias in early clinical literature stems from non-randomized observational cohorts where closed-incision NPWT was selected exclusively for extreme high-risk cases. When meta-analyses pool these small, single-center observational series with large multicenter pragmatic trials, the resulting point estimates can overstate treatment efficacy. Procurement teams must scrutinize whether trial designs utilized blind outcome assessment, intention-to-treat analysis, and clear definitions for superficial surgical site infection versus deep fascial breakdown.
Biomechanical and Physiological Differences: Closed Incision vs Open Bed
Understanding why clinical trial results cannot be transferred between settings requires analyzing the cellular and mechanical mechanics at the wound interface:
1. Dermal Apposition vs Granulation Tissue Induction: On a primarily closed incision, epidermal integrity has been surgically restored with sutures or staples. The mechanical role of negative pressure (-80 to -125 mmHg) is to relieve lateral tissue tension across the suture line, compress subcutaneous dead space, and clear hematoma micro-collections. In contrast, an open chronic wound presents exposed dermis, fascia, or muscle with continuous fibrinous or purulent exudate. Here, negative pressure causes micro-deformation of cellular membranes (micro-strain), stimulating vascular endothelial growth factor (VEGF) secretion, fibroblast proliferation, and rapid capillary sprouting.
2. Exudate Fluid Dynamics and Protein Burden: Closed surgical incisions generate low fluid volumes (typically 5 to 30 mL over 7 days), consisting primarily of serosanguinous fluid. Single-use incisional dressings absorb or transpire this fluid without requiring large vacuum canisters. Open wounds (diabetic foot ulcers, pressure injuries, open abdominal surgical wounds) exude 100 to 800 mL per day of protein-rich fluid laden with matrix metalloproteinases (MMPs) and inflammatory cytokines. Small incisional dressing pads saturate within hours if applied to open wounds, causing rapid seal loss and surrounding skin maceration.
3. Microbial Environment & Flora Profiles: Closed surgical incisions are protected by intact skin drapes during surgery, with infection risk driven primarily by superficial cutaneous flora (Staphylococcus aureus, Staphylococcus epidermidis). Open chronic wounds harbor complex polymicrobial biofilms containing Pseudomonas aeruginosa, Escherichia coli, and anaerobic species. Negative pressure alone does not sterilize an open wound bed; it manages exudate to prevent bacterial overgrowth.
Deep Dive: Wound Micro-Deformation & Cellular Mechanotransduction
The cellular response to negative pressure depends entirely on whether foam or dressing material contacts raw, exposed extracellular matrix (ECM) or intact stratum corneum:
In open wound beds, reticulated polyurethane foam pores (400 to 600 µm) pull un-opposed cell membranes into microscopic struts. This mechanical micro-strain stretches cell walls, activating integrin receptors, focal adhesion kinase (FAK), and extracellular signal-regulated kinase (ERK) pathways. This mechanical signaling cascade stimulates mitosis, collagen synthesis, and endothelial sprouting, resulting in rapid granulation tissue deposition (often 1 to 2 mm of new tissue height per 48 hours). In closed incisions, intact epidermal keratinocytes and basement membrane structures absorb the sub-atmospheric force, preventing direct micro-deformation of dermal fibroblasts. Consequently, ciNPWT acts as an external splint rather than a tissue inducer.
CDC NHSN Infection Criteria: Isolation of Superficial Dermal vs Organ-Space Infection
A critical reason why trial outcomes cannot be generalized across surgical procedures lies in the official Centers for Disease Control and Prevention (CDC) National Healthcare Safety Network (NHSN) Surgical Site Infection classification system:
Superficial Incisional SSI: Involves only skin or subcutaneous tissue of the incision, occurs within 30 days of surgery, and presents with purulent drainage or superficial bacterial isolation. Prophylactic ciNPWT directly reduces superficial incisional SSI by blunting skin tension, removing subcutaneous fluid, and sealing the incision against external skin flora.
Deep Incisional SSI: Involves deep soft tissues such as fascial and muscle layers, occurring within 30 to 90 days. Topically applied incisional NPWT has variable effects on deep fascial breakdown if subcutaneous dead space was not adequately closed during surgery.
Organ/Space SSI: Involves any part of the anatomical body opening or organ manipulated during the procedure (e.g., intra-abdominal abscess after colectomy, joint space infection after total knee replacement). Topically applied ciNPWT has zero impact on intra-abdominal organ/space infections caused by bowel contamination. When hospital committees evaluate trial literature, they must isolate superficial incisional SSI from organ/space SSI before projecting hospital cost savings.
Clinical Nursing Protocol, Seal Integrity, and Alarm Troubleshooting
In hospital wards and surgical recovery units, clinical nurses manage negative pressure devices under strict protocol standards:
Skin Preparation and Barrier Application: Peri-wound skin must be cleansed with sterile saline and dried thoroughly. Liquid skin protectant barrier film (e.g., cyanoacrylate or non-stinging acrylate film) is applied to a 5 cm radius surrounding the incision or wound margin to protect fragile skin from adhesive shear and maceration.
Drape Application and Vacuum Seal Verification: Transparent polyurethane drape is applied without stretching or tensioning the skin. When the pump is activated, the dressing should collapse rapidly, creating a firm, wrinkled appearance ('prune effect') indicating hermetic seal attainment. If the pump emits a continuous low-pressure alarm, nurses must perform a systematic leak audit along drape borders, tubing connectors, and anatomical skin folds.
Exudate Monitoring and Change Rules: For incisional dressings, fluid volume is monitored daily; if the absorbent pad becomes 80% saturated before day 7, the dressing must be replaced under sterile surgical conditions. For open-wound foam dressings, dressing changes are performed every 48 to 72 hours. If foam is left in an open wound bed past 72 hours, tissue ingrowth into PU foam pores causes severe pain and mechanical hemorrhage upon removal.
Side-by-Side Evidence Generalizability Matrix
To prevent improper evidence transfer, clinical evaluation teams must evaluate six core dimensions before citing literature in a tender, hospital formulary, or device specification:
| Evidence Dimension | Closed-Incision NPWT (ciNPWT) | Open & Chronic Wound NPWT | Can Evidence Be Generalized? |
|---|---|---|---|
| Primary Clinical Goal | Prophylactic: prevent incision breakdown, skin dehiscence, seroma/hematoma, and superficial SSI. | Therapeutic: stimulate granulation tissue, manage severe exudate, contract open wound bed, prepare for grafting. | NO — Prophylaxis on closed skin does not model healing velocity in open necrotic or chronic beds. |
| Target Population | High-risk surgical patients (BMI ≥ 30, diabetes, ASA ≥ 3, revision arthroplasty, vascular/colorectal surgery). | Open traumatic wounds, diabetic foot ulcers (DFU), pressure injuries (PI), open abdominal wounds. | NO — Patient baseline vascularity, tissue loss, and bacterial colonization profiles differ completely. |
| Primary Endpoint | Superficial Surgical Site Infection (SSI) rate within 30 to 90 days; surgical dehiscence rate. | Percentage reduction in wound surface area; median time to complete closure; granulation %. | NO — An SSI reduction percentage cannot predict area reduction or days-to-closure in an open wound. |
| Typical Device Format | Single-use, battery-powered or non-powered compact units (-80 to -125 mmHg; 0–300 mL canister/pad capacity). | Durable medical vacuum pump with large canister capacity (300–1000 mL) and continuous/intermittent modes. | NO — Compact incisional dressing pads overflow instantly if applied to high-exudate open wounds. |
| Dressing Interface | Specialized closed-incision dressing (foam or multilayer absorbent pad with silicone adhesive layer). | Reticulated polyurethane (PU) black foam (400–600 µm pores) or polyvinyl alcohol (PVA) white foam inside wound bed. | PARTIAL — Micro-strain principles apply, but foam placement and dressing mechanical shear differ. |
| Cochrane Meta-Analysis Baseline | Cochrane 2022 (CD009261): SSI 8.70% vs 11.75% (RR 0.73, moderate certainty); dehiscence RR 0.97 (no clear diff) 2. | Cochrane 2018 (CD009825): No clear difference in wound infection for open traumatic wounds; low-certainty data 4. | NO — Meta-analyses demonstrate opposite infection outcome signals across the two populations. |
Deep Dive: Closed-Incision (ciNPWT) Evidence and Guideline Boundaries
The strongest clinical backing for prophylactic closed-incision NPWT comes from systematic reviews examining high-risk surgical procedures (orthopaedic trauma, revision joint arthroplasty, vascular groin incisions, and abdominal surgery).
The 2022 Cochrane Systematic Review by Norman et al. (CD009261) represents the definitive evidence synthesis for primary closure surgical wounds 2:
- Surgical Site Infection (SSI) Reduction: Across 44 studies (11,403 participants), NPWT reduced SSI rates from 11.75% in conventional dressing controls to 8.70% in the NPWT group. This yielded a Risk Ratio (RR) of 0.73 (95% CI 0.63 to 0.85), rated as moderate-certainty evidence.
- Surgical Dehiscence: Across 23 studies (8,724 participants), NPWT showed little to no clear difference in wound dehiscence rates compared to standard dressings (RR 0.97, 95% CI 0.82 to 1.15), rated as moderate-certainty evidence.
- Mortality & Safety: Mortality showed no clear difference (RR 0.78, 95% CI 0.47 to 1.30, low certainty). However, ciNPWT was associated with an increased incidence of skin blistering and epidermal stripping in studies utilizing rigid adhesive borders without soft silicone interfaces.
- WHO 2018 SSI Guideline Framing: The World Health Organization included Recommendation 10 in its global SSI guidelines: 'The panel suggests the use of prophylactic negative pressure wound therapy on primarily closed surgical incisions in high-risk wounds...' 1 Crucially, WHO classified this as a conditional recommendation based on low-quality evidence, stressing that hospitals must consider equipment costs, staff training, and local baseline SSI prevalence before mandating routine use.
The magnitude of SSI risk reduction scales strongly with baseline patient comorbidities, an effect the Cochrane 2022 review examined in subgroup analysis. In very high-risk cohorts — poorly controlled diabetes (HbA1c > 8.0%), severe obesity (BMI ≥ 35 kg/m²), chronic kidney disease, or immunosuppression — published baseline SSI rates commonly reach 22% to 30%; applying Cochrane's pooled relative risk reduction to such a baseline yields an absolute risk reduction (ARR) approaching 8% and a Number Needed to Treat (NNT) of roughly 12 patients. Conversely, in low-risk elective procedures with baseline SSI rates below 2%, the same relative effect produces an ARR of only about 0.5%, expanding NNT beyond 200. The same relative benefit therefore buys very different absolute value depending on baseline risk — the core reason blanket ciNPWT mandates are difficult to justify.
The Large RCT Paradox: Why WHIST and SUNRRISE Conflict with Meta-Analyses
While pooled meta-analyses demonstrate a positive overall RR, large individual pragmatic RCTs have produced neutral results. Understanding why is essential for clinical procurement committees:
The WHIST Trial (Wound Healing in Surgery for Trauma, n=1,548) evaluated incisional NPWT versus standard dressings in major lower-limb fracture surgery. At 30 days, deep SSI rates were 5.8% for NPWT vs 6.7% for standard dressings (OR 0.87, 95% CI 0.57 to 1.33, p=0.52)—showing no statistically significant difference.
Similarly, the SUNRRISE Trial evaluated single-use ciNPWT in emergency bowel surgery. In colorectal surgery, deep or organ-space infections are driven primarily by endogenous gastrointestinal flora spillage during laparotomy, rather than superficial skin flora contamination 6. Because topical negative pressure acts on superficial dermal layers, it cannot prevent deep intra-abdominal abscess formation. Citing general ciNPWT SSI reduction numbers in a colorectal surgical tender without isolating superficial versus deep SSI leads to false efficacy assumptions.
Deep Dive: Open and Chronic Wound NPWT Evidence Boundaries
For open traumatic wounds, open abdomen, diabetic foot ulcers (DFU), and stage 3/4 pressure injuries, NPWT is used therapeutically to clear interstitial fluid, promote capillary sprouting, and accelerate granulation.
In the 2018 Cochrane Review on open traumatic wounds (Dumville et al., CD009825), investigators found that evidence supporting NPWT over standard moist wound dressing was of low to very low certainty 4. There was no statistically clear difference in overall wound infection rates or time to complete healing. The primary clinical benefit of open-wound NPWT lies in exudate containment and wound volume reduction prior to delayed primary closure or split-thickness skin grafting (STSG), rather than direct bacterial eradication.
Procurement leads should refer to our detailed companion report on NPWT dressing selection: PU vs PVA foam, pore size, and change intervals to evaluate how foam pore geometry (400–600 µm reticulated PU black foam vs dense PVA white foam) impacts tissue ingrowth and exudate management in open wounds.
Specialty-Specific Clinical Subgroup Analysis
The efficacy of ciNPWT varies substantially across surgical disciplines. Procurement committees should evaluate clinical trial evidence according to surgical specialty rather than applying a single hospital-wide policy:
| Surgical Specialty | Incision Profile & Infection Risk Drivers | Clinical Evidence Summary (ciNPWT) | Procurement Recommendation |
|---|---|---|---|
| Orthopaedic Joint Arthroplasty | Primary & revision total hip/knee arthroplasty; high consequences of periprosthetic joint infection (PJI). | Strong evidence for reducing superficial hematoma, seroma, and wound dehiscence in high-BMI patients. | High priority for high-BMI (BMI ≥ 35) or revision arthroplasty patient subgroups. |
| Vascular Surgery (Groin) | Femoral artery exposure, synthetic graft placement; high baseline SSI rate (15–30%) due to groin skin flora & lymphatic disruption. | Substantial RCT and meta-analysis evidence showing a notable relative risk reduction in superficial groin incision SSI in high-risk vascular patients. | High priority for all groin incision vascular reconstructions. |
| Abdominal & Colorectal Surgery | Laparotomy incisions; risk driven by endogenous fecal contamination & deep organ-space abscess. | Mixed RCT results (SUNRRISE trial neutral for deep infection); reduces superficial wound breakdown only. | Selective priority for high-BMI patients; do not expect reduction in deep intra-abdominal abscess. |
| Obstetrics (C-Section) | Pfannenstiel or vertical incision in obese parturients (BMI ≥ 30). | Multiple meta-analyses show moderate reduction in superficial surgical wound complications. | Targeted priority for high-risk obese obstetrical surgical cases. |
Economic and Hospital Readmission Impact Analysis
From a health economics perspective, the decision to implement prophylactic ciNPWT rests on calculating the baseline SSI rate ($R_{base}$), the cost of managing an SSI event ($C_{SSI}$), and the cost of the single-use NPWT device ($C_{device}$):
Economic Breakeven Threshold: C_{device} < (R_{base} × RRR × C_{SSI}), where $RRR$ is the Relative Risk Reduction achieved by ciNPWT (typically 0.27 based on Cochrane 2022).
If a vascular groin incision has a baseline SSI rate of 20% and an infected graft readmission costs $25,000 to manage, the expected cost saving per patient from ciNPWT is 0.20 × 0.27 × $25,000 = $1,350. In this setting, purchasing a $200 single-use ciNPWT dressing yields a net positive return of $1,150 per patient. Conversely, in a low-risk orthopaedic procedure with a baseline SSI rate of 1.5%, the expected saving per patient is 0.015 × 0.27 × $25,000 = $101.25. Spending $200 on ciNPWT in low-risk patients results in a net financial loss of $98.75 per case.
Adverse Event Analysis: FDA MAUDE Reporting and Clinical Mitigations
To maintain patient safety, clinical engineering and wound care specialists must understand the distinct adverse event profiles reported for incisional and open-wound NPWT devices in passive surveillance databases such as FDA MAUDE:
| Adverse Event Type | Device Category | Clinical Mechanism | Prevention & Mitigation Protocol |
|---|---|---|---|
| Epidermal Stripping & Blistering | Single-Use Incisional NPWT | Rigid adhesive drape borders pulling on fragile skin during patient movement or swelling. | Use soft silicone adhesive interface drapes; avoid tensioning skin during drape application. |
| Foam Retention & Granulation Ingrowth | Durable Open-Wound NPWT | Reticulated PU foam left in open wound bed longer than 72 hours; tissue grows into 400 µm pores. | Strict 48-to-72 hour dressing change schedule; use non-adherent wound contact layers. |
| Maceration of Peri-Wound Skin | Both Incisional & Open NPWT | Loss of vacuum seal causes fluid pooling around skin margins under adhesive drape. | Apply liquid skin barrier film to peri-wound skin; re-seal drape leaks immediately upon alarm. |
| Massive Hemorrhage / Bleeding | Durable Open-Wound NPWT | Direct foam contact over exposed blood vessels, arterial grafts, or anastomotic lines. | CONTRAINDICATED over exposed blood vessels; require protective non-adherent barrier film. |
In FDA MAUDE adverse event reports for single-use incisional dressings, skin tearing and phlyctenular blistering are among the most frequently reported device-related complications. Skin tearing occurs when rigid polyurethane drapes are pulled taut over dynamic joint surfaces (e.g., knee or hip revisions). When post-operative joint swelling occurs, the rigid adhesive drape exerts extreme shear stress on the epidermal-dermal junction, shearing epidermal layers away. Utilizing soft silicone adhesive interface drapes drastically reduces mechanical shear while maintaining hermetic seal integrity. (MAUDE is a passive-surveillance database; report counts do not establish incidence, causation, or comparative safety.)
Device Format Non-Equivalence: Technical Specification Comparison
A common mistake in hospital equipment specifications is treating single-use closed-incision systems and durable open-wound NPWT systems as interchangeable items under a single tender line. The table below details why their technical parameters require separate procurement specifications:
| Technical Feature | Prevena System (3M/Solventum) | PICO System (Smith+Nephew) | Durable NPWT Pump (VEMERIX Platform) |
|---|---|---|---|
| FDA Regulatory Clearance | 21 CFR 878.4783 (De Novo DEN180013); product code QFC 3. | 21 CFR 878.4780 / 878.4683; cleared for closed incisions & small open wounds 5. | 21 CFR 878.4780 (Powered Suction Pump); product code OMP 8. |
| Negative Pressure Level | -125 mmHg continuous preset. | -80 mmHg continuous preset. | Adjustable -40 mmHg to -200 mmHg (Continuous & Intermittent modes). |
| Exudate Handling Mechanism | 45 mL or 150 mL integrated canister; continuous battery pump unit. | Canister-free; multi-layer absorbent dressing with transpiration top layer (up to 300 mL/wk). | 300 mL, 500 mL, or 1000 mL disposable canisters with hydrophobic filter & gelling agent. |
| Maximum Operational Life | Up to 7 days (single-patient disposable unit). | PICO 7 (7 days); PICO 14 (14 days battery lifetime). | Rechargeable durable pump (5-year service life) with single-use dressing kits. |
| Target Clinical Setting | Prophylactic closed high-risk surgical incisions. | Low-to-moderate exudate closed incisions or shallow open wounds. | Moderate-to-high exudate open wounds, chronic ulcers, open abdomen, trauma. |
| Consumable Replacement | Entire system disposed after 7 days. | Dressing changed every 3–7 days; pump unit disposed after battery expiry. | Dressing change every 48–72 hours; canister replaced when full; pump reused. |
For a complete financial analysis comparing capital pump acquisition against disposable single-use systems, review our hospital cost guide: NPWT pump hospital price and total cost of therapy model.
The Clinical Evidence Pack Checklist for NPWT Tenders
When structuring an RFQ or evaluating vendor claims for NPWT systems, clinical engineering and hospital procurement teams should mandate that vendors submit an Evidence Pack categorized by intended indication:
- Indication-Specific Trial Data: Require separate peer-reviewed evidence for closed surgical incisions versus open/chronic wounds. Reject tenders that cite closed-incision SSI reduction percentages to justify open-wound healing claims.
- Endpoint Breakdown: Ensure the submitted studies report absolute risk reductions (ARR) and Number Needed to Treat (NNT), rather than relative risk (RR) alone. For example, a drop from 11.75% to 8.70% SSI yields an ARR of 3.05% and an NNT of approximately 33 patients.
- Superficial vs Deep Infection Distinction: Verify whether trial endpoints isolated superficial dermal SSI or included deep organ-space infection, particularly for abdominal and pelvic surgical tenders.
- Device Pressure and Exudate Matching: Require vendors to state the operating pressure (-80, -125, or adjustable -40 to -200 mmHg) and fluid capacity limits (canister volume vs transpiration rate) for the exact model offered.
- Regulatory Compliance File: Verify 510(k) summary, EU MDR CE certificate, or NMPA registration matching the device trade name. Ensure non-powered (QPX) and powered (OMP) systems are evaluated under appropriate tender lots.
When evaluating Health Technology Assessment (HTA) submissions from device vendors, procurement teams should require sensitivity analyses demonstrating how local hospital labor costs and operating room readmission expenses alter net financial returns. If a vendor's budget impact model relies solely on US Medicare reimbursement assumptions, the results will not translate accurately to European single-payer health systems or emerging market hospital networks.
To download sample tender specifications and technical matrix templates, refer to our comprehensive procurement guide: how to specify an NPWT system for tender and RFQ.
Where VEMERIX Fits—and Where Due Diligence Begins
VEMERIX provides a total solution platform for perioperative care, incorporating both the durable medical vacuum pump and disposable drainage dressing kits:
- VEMERIX Medical Vacuum NPWT Pump: Engineered for versatile hospital and homecare use, featuring adjustable continuous and intermittent pressure modes (-40 mmHg to -200 mmHg), intelligent pressure monitoring, dual-power safety systems, and silent operation. Explore the system on the VEMERIX NPWT Pump product page.
- VEMERIX Disposable Drainage Dressing Kit: Available with biocompatible reticulated foam, hydrophobic drape seals, variable canister options (300 mL / 500 mL / 1000 mL), and multi-port tubing connectors compatible with standard surgical suction systems. Details are on the VEMERIX NPWT Dressing product page.
- Due Diligence Boundary: VEMERIX advocates transparent evidence matching. Our durable NPWT pump and high-capacity dressing kits are engineered primarily for moderate-to-high exudate open, chronic, and surgical wounds. While our systems can deliver continuous -125 mmHg for incisional care, hospitals evaluating single-use canister-free prophylactic incisional therapy should perform a clinical cost-benefit analysis comparing single-use incisional dressings with durable pump platforms before finalizing procurement.
Frequently Asked Questions
Does the SSI-reduction evidence for closed-incision NPWT apply to healing open or chronic wounds?
No. Closed-incision NPWT evidence (such as the 2022 Cochrane Review showing an SSI reduction from 11.75% to 8.70%) evaluates prophylactic infection reduction on primarily closed surgical skin. Open and chronic wounds evaluate tissue granulation rates, wound area contraction, and time to complete re-epithelialization. Citing closed-incision SSI outcomes to predict chronic wound healing rates is a methodological error.
Are single-use incisional systems (e.g., PICO, Prevena) interchangeable with durable open-wound NPWT systems (e.g., V.A.C., VEMERIX)?
No. Single-use incisional systems are pre-set to fixed negative pressures (-80 or -125 mmHg) and have limited fluid handling capacity (canister-free transpiration or small 45–150 mL canisters). Applying them to high-exudate open wounds causes rapid dressing saturation, loss of vacuum seal, and skin maceration. Conversely, durable pumps offer high-capacity canisters (300–1000 mL), adjustable pressure ranges (-40 to -200 mmHg), and continuous/intermittent modes designed for heavy exudate and thick foam dressing beds.
Why does WHO rate the prophylactic-incision NPWT recommendation as conditional, and what does that mean for procurement?
In its 2018 Global SSI Prevention Guidelines (Recommendation 10), WHO classified prophylactic ciNPWT as a conditional recommendation based on low-quality evidence. This rating reflects the variable quality of underlying trials, the absence of clear mortality benefit, and the economic burden of single-use devices. For hospital procurement teams, this means ciNPWT should be targeted selectively at high-risk patient subgroups (e.g., severe obesity, revision arthroplasty, emergency vascular groin incisions) rather than deployed as an unvetted baseline for all surgical cases.
What is the difference between superficial SSI and deep organ-space infection when evaluating NPWT trials?
Superficial SSI involves only skin and subcutaneous tissue of the incision. Deep organ-space infection involves anatomical structures (such as the peritoneal cavity or periprosthetic joint space) opened or manipulated during surgery. Topical NPWT directly reduces tension and clears seroma in superficial dermal layers, but it cannot prevent deep intra-abdominal or pelvic abscesses caused by GI tract contamination during surgery. Clinical tenders must separate superficial from deep SSI endpoints.
How long should a closed-incision NPWT dressing be kept in place post-operatively?
Most clinical trial protocols leave single-use closed-incision NPWT dressings in place undisturbed for 5 to 7 days post-operatively. Early removal increases the risk of epidermal shearing and breaks the sterile barrier over the healing surgical line. If dressing saturation or vacuum seal alarm occurs before day 5, the dressing should be inspected by the surgical team.